Overcoming obstacles to the success of protease inhibitors in highly active antiretroviral therapy regimens

AIDS Patient Care and STDs

Volumn 16, Issue 12, 2002, Pages 585-597

  Moyle, Graeme ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LIPID; MOZENAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; DIABETES MELLITUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; LIVER TOXICITY; METABOLIC DISORDER; NAUSEA; NEPHROLITHIASIS; NONHUMAN; PATIENT COMPLIANCE; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT FAILURE; VIRUS RESISTANCE; VOMITING;

EID: 0036908703     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729102761882125     Document Type: Review

References (70)

1. Moyle G. Use of HIV protease inhibitors as pharmacoenhancers. AIDS Read 2001;11:87-98.
2. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-Week results. AIDS 2001;15:Fl-F9.
3. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-1883.
4. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-1316.
5. Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 2000;356:993-997.
6. Moyle G, Baldwin C, Mandalia S, Comitis S, Burn P, Gazzard B. Changes in metabolic parameters and body shape after replacement of protease inhibitor with efavirenz in virologically controlled HIV-1-positive persons: Single-arm observational cohort [editorial]. J Acquir Immune Defic Syndr 2001;28:399-401.
7. Moyle G, Baldwin C. Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution. AIDS Read 2000;10:479-485.
8. Moyle G. The etiology of metabolic and morphological changes during antiretroviral therapy: Many small pieces in a large jigsaw. AIDS Rev 2001;3:75-81.
9. Piccinini M, Rinaudo MT, Chiapello N, et al. The human 26S proteasome is a target of antiretroviral agents. AIDS 2002;16:693-700.
10. Liang JS, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001;7:1327-1331.
11. Moyle G. Adverse effects of therapy: It's not just lipodystrophy. 2001. 8th Conference on Retroviruses and Opportunistic Infections; Chicago, IL; February 4-8, 2001. Available at: www.medscape.com/Medscape/CNO/2001/RETRO/Story.cfm?story_id=2056. Accessed August 2, 2001.
12. Moyle GJ, Gazzard BG. A risk-benefit assessment of HIV protease inhibitors. Drug Saf 1999;20:299-321.
13. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquire Immune Defic Syndr 2000;23:35-43.
14. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. 2001. August 13, 2001 version. Available at: hivatis.org/trtgdlns. html. Accessed February 5, 2001.
15. DHHS Guidelines for the use of antiretroviral agents in HIV-infected adults & adolescents. 2000. Supplement published by the Journal of the International Association of Physicians in AIDS Care Monthly. Available at: www.iapac.org/guideline/index.html. Accessed September 28, 2000.
16. Pozniak A, Gazzard B, Babiker D, et al. British HIV association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine 2001;2:276-313.
17. Piliero PJ. The utility of inhibitory quotients in determining relative potency of protease inhibitors. AIDS 2002;16:799-800.
18. Pantaleo G, Sanne I, Cahn P, et al. Atazanavir (BMS-232632): 48-Week safety and efficacy vs nelfinavir, each in combination with stavudine and lamivudine, in treatment-naive, HIV-positive subjects (AI324-008) [abstract 011]. Presented at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection; Athens, Greece; October 29, 2001.
19. Zucker S, Qin X, Rouster S, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001;98:12671-12676.
20. Cahn P. Tipranavir: A next-generation protease inhibitor with potential value for experienced patients. 2001. CME activity from Medscape based on presentations at the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; July 9, 2001. Available at: www.medscape.com/Medscape/CNO/public/Stories.cfm?conference_id=127& day_num=2. Accessed August 20, 2001.
21. Haas D, Zala C, Schrader S, Thiry A, McGovern R, Schnittman S. Once-daily atazanavir plus saquinavir favorably affects total cholesterol (TC) and fasting triglyceride (TG) profiles in patients failing prior PI therapy (trial AI424-009, wk 24) [slide session LB-16]. 2001. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; December 18, 2001. Available at: www.thebody. com/confs/icaac2001/boyle6.html. Accessed March 21, 2002.
22. Sanne IM. Recent developments in treatment-associated adverse events. 2000. CME activity from Medscape based on presentations made at the 5th International Congress on Drug Therapy in HIV Infection; October 22, 2000. Available at: www.medscape.com/ medscape/cno/2000/ICDT/Story.cfm?story_id=173 7. Accessed November 9, 2001.
23. Squires K, Cahn P, Pantaleo G, et al. Atazanavir: A once-daily protease inhibitor with a superior lipid profile in antiretroviral (ARV)-naïve and -experienced patients [abstract]. Presented at the World Congress of Cardiology; Syndey Australia; May 5-9, 2002.
24. Colonno RJ, Friborg J, Rose RE, Lam E, Parkin N. Identification of amino acid substitutions correlated with reduced atazanavir susceptibility in patients treated with atazanavir containing regimens. Antimicrob Agents Chemother (in press).
25. Haas DW, Zala C, Schrader S, Thiry A, McGovern R, Schnittman S. Atazanavir plus saquinavir once daily favorably affects total cholesterol (TC), fasting triglyceride (TG), and fasting LDL cholesterol (LDL) profiles in patients failing prior therapy (trial AI424-009, week 48) [abstract 42]. 2002. Presented at 9th Conference for Retroviruses and Opportunistic Infections; Seattle, WA; February 24-28, 2002. Available at: 63.126.3.84/2002/Abstract/13797.htm. Accessed March 13, 2002.
26. Rusconi S, La Seta Catamancio S, Citterio P, et al. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother 2000;44: 1328-1332.
27. Curry R, Markowitz M, Slater L, Neubacher D, Robinson P, Cotton G. Safety and efficacy of tipranavir, a non-peptidic protease inhibitor, in multiple PI-failure patients (BI 1182.2). 2001. International AIDS Society Conference on HIV Pathogenesis and Treatment; Buenos Aires, Argentina; July 8-11, 2001. Available at: www.ias.se/abstract/show.asp?abstract_id=3. Accessed November 8, 2001.
28. Youle M. Investigational antiretrovirals in existing classes. 2001. CME activity from Medscape based on presentations at the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Day 2; July 9, 2001. Available at: www.medscape.com/ Medscape/CNO/public/Stories.cfm?conference_id =127&day_num=2. Accessed August 20, 2001.
29. Hodge CN, Aldrich PE, Bacheler LT, et al. Improved cyclic urea inhibitors of the HIV-1 protease: Synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem Biol 1996;3:301-314.
30. Sierra-Madero J. Antiviral Activity, Safety, and Pharmacokinetics of Mozenavir (DMP 450), a Novel Cyclic Urea Protease Inhibitor, in Combination with D4T and 3TC in Treatment-naive HIV-1 Infected Patients (Study DMP-102). 2001. Available at: www.ias.se/abstract/show.asp?abstract_id=2. Accessed November 6, 2001.
31. Bini T, Testa L, Chiesa E, et al. Outcome of a secondline protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;24:115-122.
32. Reijers MHE, Weigel HM, Hart AAM, et al. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. AIDS 2000;14:59-67.
33. d'Arminio Monforte A, Cozzi Lepri A, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS 2000;14:499-507.
34. Paparizos VA, Kyriakis KP, Botsis C, Papastamopoulos V, Hadjivassiliou M, Stavrianeas NG. Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus. AIDS 2000;14:903-905.
35. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-F70.
36. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Arch Intern Med 2000;160:2050-2056.
37. Powderly WG. Adverse effects of antiretroviral therapy: More noise, less clarity? 2001. CME activity from Medscape based on presentations at the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; July 9, 2001. Available at: www.medscape.com/Medscape/CNO/public/Stories.cfm?conference_id=127& day_num=2. Accessed August 2, 2001.
38. Duncombe C. Reversal of hyperlipidemia and lipodystrophy in patients switching therapy to nelfinavir [letter]. J Acquir Immune Defic Syndr 2000;24:78-79.
39. Mauss S, Wolf E, Corzillius M, et al. Prevalence and risk factors for the HIV-associated lipodystrophy syndrome (HALS) in patients being 3 years on ART [abstract 1287]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Ontario, Canada; September 17-20, 2000. Herndon, VA: ASM Press.
40. Moyle G. Controversies in antiretroviral management: The need for simpler, cheaper, and safer therapy. 2000. CME activity from Medscape based on presentations at the XIII International AIDS Conference; July 14, 2000. Available at: www.medscape.com/Medscape/CNO/2000/AIDS/Story.cfm?story_id=1 482. Accessed August 2, 2001.
41. Petit JM, Duong M, Duvillard L, et al. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: A longitudinal study. Horm Metab Res 2000;32:367-372.
42. Jütte A, Schwenk A, Franzen C, et al. Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? AIDS 1999;13:1796-1797.
43. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104:257-262.
44. van der Malk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1-infected patients results in an antiatherogenic lipid profile. AIDS 2001;15:2407-2414.
45. Falusi OM, Aberg JA. HIV and cardiovascular risk factors. AIDS Read 2001;11:263-268.
46. Dubé MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000;31:1216-1224.
47. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
48. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 2001;15:1503-1508.
49. Dubé MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000;31:1467-1475.
50. Gan SK, Samaras K, Carr A, Chisholm D. Anti-retroviral therapy, insulin resistance and lipodystrophy. Diabetes Obes Metab 2001;3:67-71.
51. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001;15:F11-F18.
52. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20251-20254.
53. Parker RA, Wang S, Meyers D, Fenderson W, Mulvey R, Leet J et al. Differentiation of HIV protease inhibitors in models of lipid and glucose metabolism and gene expression in adipocytes and hepatocytes [abstract]. Abstract Presented at the International Workshop on Adverse Drug Reactions and Lipodystrophy; Athens, Greece; October 23-26, 2001. Antivir Ther (in press).
54. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
55. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-366.
56. Hogg RS, Yip B, Chan K, O'Shaughnessy V, Montaner JSG. Nonadherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women [abstract 73]. 2000. 7th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; January 30-February 2, 2000. Available at: www.retroconference.org/2000/abstracts/73.htm. Accessed September 27, 2000.
57. Vibhagool A, Cahn P, Schechter M, et al. Abacavir/combivir (ABC/COM) is comparable to indinavir/combivir in HIV-1 infected antiretroviral therapy naive adults: Preliminary results of a 48-week open label study (CNA3014) [abstract]. 2001. 1st International AIDS Society Conference on HIV Treatment and Pathogenesis; Buenos Aires, Argentina; July, 8-11, 2001. Available at: www.ias.se/abstract/show.asp?abstract_id=63. Accessed August 20, 2001.
58. Maggiolo F, Migliorino M, Maserati R, et al. Once-a-day treatment for HIV infection: final 48-week results [abstract 320]. 2001. 8th Conference on Retroviruses and Opportunistic Infections; Chicago, IL; February 6, 2001. Available at: www.retroconference.org/2001/abstracts/abstracts/abstracts/320.htm. Accessed August 28, 2001.
59. Murri R, Ammassari A, Gallicano K, et al. Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr 2000; 24:123-128.
60. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999;13:1099-1107.
61. Parienti JJ, Verdon R, Massari V, et al. Patient's factors associated with overestimation of adherence to antiretroviral drugs by prescribing physicians [abstract 795]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Ontario, Canada; September 17-20, 2000. Herndon, VA: ASM Press.
62. Burman WJ, Sharkey L, James S, Joyner J, Hamilton P, Rosky J. Adherence with antiretroviral therapy: A comparison of self-reported adherence with pharmacy records [abstract 358]. 2000. 38th Annual Meeting of Infectious Diseases Society of America; New Orleans, LA; September 7-10, 2000. Available at: www.journals.uchicago.edu/CID/journal/issues/v31n1/abstracts/idsa. abstracts.pdf. Accessed September 27, 2000.
63. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-1310.
64. Gisolf EH, van Heeswijk RPG, Hoetelmans RWM, Danner SA. Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir. AIDS 2000;14:801-805.
65. Martinez-Picado J, DePasquale MP, Kartsonis NA, et al. Selection of antiretroviral resistance in the latent reservoir of human immunodeficiency virus type 1 during successful therapy [abstract 238]. 2000. 7th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; January 30-February 2, 2000. Available at: www.retroconference.org/2000/abstracts/238.htm. Accessed September 27, 2000.
66. Acosta EP, Havlir DV, Richman DD, et al. Pharmacodynamics (PD) of indinavir (IDV) in protease naive HIV-infected patients receiving ZDV and 3TC [abstract 455]. 2000. 7th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; January 30-February 2, 2000. Available at: www.retroconference.org/2000/abstracts/455.htm. Accessed October 2, 2000.
67. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study. AIDS 2000;14:1333-1339.
68. Kilby JM, Sfakianos G, Gizzi N, et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother 2000;44:2672-2678.
69. Little SJ. Transmission and prevalence of HIV resistance among treatment-naive subjects. Antivir Ther 2000;5:33-40.
70. Little SJ, Routy JP, Daar ES, et al. Antiretroviral drug susceptibility and response to initial therapy among recently HIV-infected subjects in North America [abstract 756]. 2001. 8th Conference on Retroviruses and Opportunistic Infections; Chicago, IL; February 4-8, 2001. Available at: www.retroconference.org/2001/abstracts/abstracts/abstracts/756.htm. Accessed February 15, 2001.